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Introduction 
 
Cowden syndrome is an autosomal dominant genetic disease with an estimated incidence of 1 
in 200,000. Affected individuals develop multiple systemic hamartomas and have a 
cumulative lifetime risk of breast cancer of 85%
1
. Approximately 80% of patients with 
Cowden syndrome have a germline inactivating mutation in PTEN (10q23.3)
2
. PTEN acts as 
a tumor suppressor gene (TSG) via numerous mechanisms
3
, one of which is antagonizing the 
PI3K/AKT/mTOR signaling pathway by dephosphorylating phosphatidylinositol (3,4,5)-
trisphosphate (PIP3). PIP3 functions as a secondary messenger in the PI3K pathway that 
binds and activates proteins that have a pleckstrin homology domain, such as AKT1, and 
triggers their activation and localization to the plasma membrane promoting cellular 
proliferation and survival
4
. 
Germline PTEN loss of function mutations may result in dominant AKT activation as a 
driving oncogenic event in Cowden-related breast tumours
5
. Pre-clinical evidence suggests 
that cancers with AKT activation have increased sensitivity to AKT inhibition
6
. Preliminary 
clinical evidence is derived from phase I and II trials in patients with breast cancers bearing 
somatic mutations in the PI3K-PTEN-AKT pathway
7-11
.  
Capivasertib (AZD5363, AstraZeneca) is a potent and selective oral inhibitor of all 3 
isoforms of the serine/threonine kinase AKT (AKT1, 2, 3) with pre-clinical evidence of 
efficacy as monotherapy or in combination with cytotoxic and targeted therapies
12-15
. Despite 
the encouraging progression-free survival observed with capivasertib monotherapy in heavily 
pretreated patients with AKT1 E17K-mutant breast and gynecologic cancers
9
, RECIST 
response rates in phase 1 studies only reached  22% 
8,9,16
 (Table 1). Since PTEN loss activates 
AKT1, we hypothesized that tumors from patients with Cowden syndrome could be sensitive 
to this drug family.  
Case Series  29
th
 August 2019 
 
5 
 
 
Case 1 – SAFIR02 Trial 
 
A 50-year-old woman with a family history of Cowden syndrome was diagnosed with a 
T3N3 breast cancer, estrogen (ER) and progesterone (PR) receptor-negative, HER2-negative 
grade III invasive carcinoma of no special type (NST). The patient received 6 cycles of neo-
adjuvant EC-T (cyclophosphamide 600 mg/m
2
, epirubicin 75 mg/m
2
, docetaxel 100 mg/m
2
) 
prior to a mastectomy with left axillary lymph node dissection (revealing residual disease in 
10 of 18 lymph nodes) and adjuvant radiotherapy. 
 
Eight months later the patient relapsed with cutaneous disease and thoracic nodal 
involvement. After enrolling in SAFIR02 (NCT02299999), targeted panel sequencing (Ion 
Torrent PGM) of a fresh tumor biopsy revealed the presence of a heterozygous germline 
PTEN mutation (c.389G>A, p.R130Q, SNP rs121909229) alongside other variants (Figure 
1A and Supplementary Table S1). Immunohistochemistry revealed lack of PTEN expression 
in the tumor (Figure 1B). The patient received six cycles of paclitaxel (90mg/m
2
 days 1, 8, 
and 15 of a 28 day cycle) with bevacizumab (10 mg/m
2
 on days 1 and 15), and carboplatin 
(AUC2, days 1, 8, and 15 of a 28 day cycle, ceased after 6 weeks). 
 
Upon completion of chemotherapy, tumor evaluation demonstrated a partial response 
(RECIST 1.1) with 60% reduction of target lesions (Figure 1C). In the context of SAFIR02, 
the patient was randomized to maintenance targeted therapy, and received capivasertib 480 
mg BID 4 days on 3 days off. This treatment was well tolerated with no grade 2 or above 
toxicities. After 3-months of capivasertib monotherapy, a complete response was observed, 
which was maintained for 12 months before the patient progressed on capivasertib. 
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Case 2 – BEECH Trial 
In March 2010 a 37-year-old woman with known Cowden syndrome and a history of a neck 
arteriovenous malformation, multinodular goiter and rectal hamartomatous polyps was 
diagnosed with bilateral breast cancer. On the right, she presented with a T3, ER- and PR-
positive, HER2-negative grade II invasive carcinoma NST with 20 out of 23 involved lymph 
nodes. On the left, she presented with a 4mm grade II invasive carcinoma NST, strongly ER-
positive and HER2-negative.  Following a bilateral mastectomy, exome sequencing 
(Hiseq2500) of the right breast cancer and germline DNA revealed the germline PTEN 
mutation (c.T68G:p.L23X), and a ‘second hit’ somatic stop-gain PTEN mutation (exon 1, 
c.T264A:p.Y88X) with an AF of 25.5%, alongside other variants (Figure 2A and 
Supplementary Table S1). PTEN immunohistochemistry revealed reduced PTEN staining in 
the tumor (Figure 2B). Post-operative staging revealed metastatic disease, with mediastinal 
lymph nodes and lung metastases. In May 2010 the patient received 6 cycles of 3-weekly 
FEC chemotherapy (fluorouracil 600 mg/m
2
, epirubicin 75 mg/m
2
, cyclophosphamide 600 
mg/m
2
) before starting maintenance tamoxifen. In October 2011, she had a bilateral salpingo-
oophorectomy.  
After 28-month progression-free period, the patient was found to have new liver metastases. 
In November 2012 she enrolled in the phase 1/2 BEECH study (NCT01625286) and was 
assigned to receive paclitaxel plus capivasertib (Part A, Schedule 2). She received eight 
cycles of paclitaxel (90mg/m2 days 1, 8, and 15 of a 28-day cycle) combined with 
capivasertib (360mg BID on days 2-5, 9-12, 16-18 of each 28-day cycle). In June 2013, a CT 
showed a complete response of the liver metastases. The patient continued maintenance 
capivasertib alone with no grade 2 or above toxicities.  She had a confirmed maintained 
response in May 2014 until progression in June 2014, giving a PFS of 19 months, and a 
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maintained complete response of 12 months on capivasertib alone (Figure 2C).  Plasma 
ctDNA analysis from baseline and progression time points during the BEECH study showed 
no major changes (Supplementary Table S1). 
Discussion 
The AKT inhibitor capivasertib has been examined in early phase trials (Table 1) and no 
complete responses have been noted, yet both patients with Cowden syndrome presented here 
had durable complete responses to capivasertib. Such outlier sensitivity likely reflects the 
germline, and therefore fundamentally clonal, nature of PTEN alteration. In vivo mice models 
with PTEN homozygous deletion have shown dramatic regression of the Cowden phenotype 
features of trichilemmomas on treatment with mTOR (downstream from AKT) inhibitor 
rapamycin
17
. In humans, Hyman et al demonstrated that tumor response to targeted treatment 
with capivasertib was proportional to AKT1 mutation clonality
9
. Furthermore, three case 
reports in pediatric patients and a pilot study (n=18) in adults with PTEN aberrations have 
shown regression of phenotypic changes associated with PTEN loss after treatment with 
mTOR inhibitor sirolimus
18-21
, demonstrating sensitivity of even non-malignant cells carrying 
a germline PTEN mutation to PI3K-pathway inhibition. Similarly to the cases presented here, 
no severe toxicity was noted in the pilot study
21
, with just one patient experiencing a Grade 3 
AE (hypophosphatemia/hypercholesterolaemia). 
In recent years drugs targeting the PI3K/AKT/mTOR pathway have been developed. Trials 
have attempted to identify molecular predictors of response by identifying alterations in the 
PI3K/AKT/mTOR pathway (Supplementary Table S2). Tumor PIK3CA mutations are not 
clear predictors of response to mTOR inhibition.  In contrast, AKT inhibitors in combination 
with paclitaxel have been shown to be more active in patients with triple negative breast 
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cancers harboring a PIK3CA/PTEN/AKT1 pathway alteration.
7,22
 Similarly, PI3kinase 
inhibitors have demonstrated activity in patients with PIK3CA mutations
23,24
. 
Of note in Case 2 is the presence of the second-hit PTEN stop-gain mutation Y88X present 
with an AF of 25.5%. However, the presence of a TP53 mutation at an AF of 51.9% indicates 
that this ‘second-hit’ mutation is subclonal rather than a truncal driver mutation. Conversely 
Case 1 does not have a PTEN second-hit mutation or loss of heterozygosity (LOH) yet 
demonstrates lack of PTEN expression. Low tumor purity can make LOH difficult to detect, 
and whilst the estimated purity was 40%, the true purity may have been lower. Explanations 
for the PTEN phenotype in Case 1 include undetected LOH, PTEN promotor 
hypermethylation
25,26
, complex PTEN genomic rearrangements
27
 and post-translational 
modification
28
. 
Contrary to Knudson’s ‘two-hit’ model of tumorigenesis in TSGs29, PTEN aberrations appear 
to be pro-tumorigenic in the absence of a ‘second hit’. In 2010, Alimonti et al demonstrated 
that PTEN hypermorphic mice (with 80% of normal PTEN protein level) had a greater 
propensity to tumorigenesis than mice with two functional alleles, but were less tumorigenic 
than PTEN heterozygous mice
30
, supporting a haploinsuffiency model of tumorigenesis in 
PTEN aberrations.  
A later in vivo study of PTEN knock-in mice models suggested that the conformation of 
PTEN underlies the dominant-negative behavior of PTEN heterozygous mutants. Papa et al
31
 
demonstrated that PTEN is catalytically active in PIP3 dephosphorylation and subsequent 
downstream PI3K/AKT/mTOR pathway regulation, after dimerization. Significantly, mutant 
PTEN protein was able to dimerize with wild type PTEN but the resultant hetero-dimers were 
less able to hydrolyze PIP3. Moreover, mutant PTEN outcompeted and displaced wild type 
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PTEN protein in dimerization and membrane localization. This supports the rationale that 
PTEN heterozygous mutants act in a dominant-negative manner to promote tumorigenesis. 
The cases presented here were treated with combination chemotherapy and capivasertib 
followed by capivasertib monotherapy. The patient in Case 1 had previously demonstrated 
tumor resistance to taxane therapy, with residual disease following neo-adjuvant 
chemotherapy and a short progression free survival after treatment for primary breast cancer. 
The second patient achieved a complete response with the combination of paclitaxel and 
capivasertib, and maintained this complete response for a period of 12 months on capivasertib 
alone, suggesting that capivasertib was highly active in this patient. 
In summary, these two breast cancer patients with different germline PTEN mutations both 
showed a dramatic response to capivasertib superior to that seen in early trials of the drug. 
The excellent response in these two patients, despite their differing histology, is a promising 
indication that targeted AKT therapy is an effective approach in patients with germline PTEN 
mutations. 
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Figure and Table Legends 
 
Table 1. Summary of main phase I clinical trials with capivasertib monotherapy. 
Figure 1 Exceptional response in patient with germline PTEN R130Q mutation.  
A. Germline PTEN mutation c.389G>A, pR130Q. Illustration from 
https://proteinpaint.stjude.org. B. Immunohistochemistry demonstrating (i) absent PTEN 
staining in the tumor, (ii) cytoplasmic and membranous expression of pAKT in the 40% of 
tumor cells. C. CT scans during the patient’s time on capivasertib, white arrows indicating 
axillary disease. (i), September 2015, baseline CT showing two areas of axillary 
lymphadenopathy. (ii) January 2016, CT scans demonstrating partial response following 4 
months of Carboplatin-Paclitaxel-Bevacizumab chemotherapy. (iii) December 2016, CT 
scans following 11 months of capivasertib monotherapy demonstrating persistent complete 
response before progression in February 2017.   
 
Figure 2. Exceptional response in patient with germline PTEN L23X mutation.  
A. Germline PTEN mutation c.T68G:p.L23X and “second hit” PTEN mutation 
c.T264A:p.Y88X. Illustration from https://proteinpaint.stjude.org.  B. PTEN 
immunohistochemistry from control tissue (i), and non-cancerous (ii) and tumor-containing 
lymph node (iii and iv). The control tissue shows mainly cytoplasmic expression of PTEN. 
The non-cancerous lymph node and the residual lymphatic tissue in the lymph node 
metastasis (*) also show a PTEN expression comparable with the control. The tumor cells in 
the lymph node metastasis display weaker PTEN staining, which is mainly nucleolar. C. CT 
scans during the patient’s time on capivasertib, white arrows indicating disease in the liver. 
(i) October 2012, baseline CT demonstrating a liver deposit. (ii) January 2013, CT following 
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2 cycles of paclitaxel and capivasertib. (iii) CT demonstrating continued complete response 
on maintenance capivasertib 7 months after cessation of paclitaxel. (iv) May 2014, final CT 
before progression June 2014. 
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Table 1. Summary of main phase I clinical trials with capivasertib monotherapy. 
Trial Phase Number 
of 
Patients 
Key Eligibility Treatment 
Regimen 
Results 
Banerji et al, 
20188 
NCT01226316 
I  Part A and 
B: 90 
Part C: 59 
Parts A and B: 
Advanced solid 
malignancy 
(Western dose 
finding) 
 
Part C: ER+ or 
HER2+ breast 
cancer or 
gynecological 
cancer with 
PIK3CA 
mutation 
 
 
Part A and B: 
dose escalation 
and expansion at 
multiple dosing 
schedules1  
 
Part C: dose 
expansion of 
capivasertib at 
monotherapy 
RP2D (480mg 
BD for 4 days 
on, 3 days off) 
Part A and B: 1 
confirmed PR in 
PIK3CA mutant cervical 
cancer patient. 27 (30%) 
and 6 (7%) of patients 
had SD for ≥6 and ≥12 
weeks, respectively. 
 
Part C: Of 54 included in 
the RECIST assessment, 
3 (5.6%) had a 
confirmed PR, of whom 
1 of 28 (4%) in the ER+ 
breast cancer cohort and 
2 of 26 (8%) in the 
gynecological cancer 
cohort 
Hyman et al, 
20179 
NCT01226316 
I 59 
(Evaluable 
=58) 
Part D: ER+ or 
HER2+ breast 
cancer, 
gynecological 
cancer, all other 
solid tumors with 
AKT1 mutation 
(E17K, n = 52; 
non-E17K, n = 5; 
AKT1 mutation 
not detected, n = 
1). 
 
Part D: dose 
expansion at 
monotherapy 
RP2D 480mg 
BD for 4 days 
on, 3 days off. 
Confirmed PR in 10 of 
58 (17.2%), of whom 4 
of 20 (20%) patients in 
the ER+ breast cancers 
cohort, 4 of 18 (22.2%) 
patients in the 
gynecological cancers 
cohort, and 2 of 20 
(10.0%) patients in the 
other solid tumor cohorts 
(triple-negative breast 
cancer and lung 
adenocarcinoma, n = 1 
each).  
Tamura et al, 
201616 
NCT01353781 
I 
 
41 Advanced solid 
malignancy 
(Japanese dose 
finding) 
Dose escalation 
at multiple 
dosing 
schedules2  
Of 37 evaluable patients, 
2 (5.4%) had confirmed 
PR, and 10 (27%) had 
SD for ≥6 weeks. 
Abbreviations: ER+, estrogen receptor positive; HER2+, HER2 positive; HER2-, HER2 negative; RP2D, 
recommended phase II dose; PR, partial response; SD, stable disease. 
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Figure 1. Exceptional response in patient with germline PTEN R130Q mutation. 
 
 
 
 
Figure 2. Exceptional response in patient with germline PTEN L23X mutation. 
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